{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-047188","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.342818+00:00","generated_at":"2026-05-17T01:37:03.622294+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vistagen appoints Paul Edick to Board of Directors, effective October 27, 2025","bullets":["Mr. Edick appointed to Board, Audit Committee, and Compensation Committee.","Received options to purchase 35,200 shares at $3.90/share (closing price on appointment date), vesting over 3 years.","He is entitled to annual cash and equity compensation under the Director Compensation Plan.","Mr. Edick is former Chairman/CEO of Xeris Pharmaceuticals and ex-CEO of Durata Therapeutics.","No family relationships or transactions with the company requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-047188","json":"https://secwatch.observer/filing/0001628280-25-047188.json","markdown":"https://secwatch.observer/filing/0001628280-25-047188.md","text":"https://secwatch.observer/filing/0001628280-25-047188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025047188/0001628280-25-047188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025047188/vtgn-20251027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:37:03.622294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}